guest ::
| Home > Publications database > IGLV3-21R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia. > print |
| Home > Publications database > IGLV3-21R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia. > print |
| 001 | 304502 | ||
| 005 | 20250914022659.0 | ||
| 024 | 7 | _ | |a pmid:40931870 |2 pmid |
| 024 | 7 | _ | |a 0390-6078 |2 ISSN |
| 024 | 7 | _ | |a 1592-8721 |2 ISSN |
| 024 | 7 | _ | |a DOI:10.3324/haematol.2025.287697 |2 doi |
| 024 | 7 | _ | |a DOI:10.3324/haematol.2025.287697 |2 doi |
| 024 | 7 | _ | |a altmetric:181352533 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01891 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Fischer, Claudia |b 0 |
| 245 | _ | _ | |a IGLV3-21R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia. |
| 260 | _ | _ | |a Pavia |c 2025 |b Ferrata Storti Foundation |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1757593897_7394 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a epub |
| 520 | _ | _ | |a We previously used a disease-specific B cell receptor (BCR) point mutation (IGLV3-21R110) for selective targeting of a high-risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR) T cells. Since CLL is a disease of the elderly and a significant fraction of patients is not able to physically tolerate CAR T cell treatment, we explored bispecific antibodies as an alternative for precision targeting of this tumor mutation. Heterodimeric IgG1-based antibodies consisting of a fragment crystallizable region (Fc) attached to both an anti-IGLV3-21R110 Fab and an anti-CD3 (UCHT1) single chain variable fragment (R110-bsAb) selectively killed cell lines engineered to express high levels of the neoepitope as well as primary CLL cells using healthy donor and CLL patient-derived T cells as effectors. R110-bsAb spared polyclonal human B cells (as opposed to CD19-targeting Blinatumomab) as well as CD34+ human stem cells. Yet, R110- bsAb induced lower T cell activation than Blinatumomab with primary CLL cells likely due to lower expression of target antigen. In vivo, R110-bsAb specifically killed IGLV3-21R110-expressing cell lines and CLL cells while sparing peripheral blood mononuclear cells. These findings highlight bispecific antibodies as a potential off-the-shelf immunotherapy for high-risk CLL patients, offering selective targeting while preserving healthy B cells. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Chen, Shih-Shih |b 1 |
| 700 | 1 | _ | |a Nimmerfroh, Johanna |b 2 |
| 700 | 1 | _ | |a Eugster, Anne |b 3 |
| 700 | 1 | _ | |a Stücheli, Simon |b 4 |
| 700 | 1 | _ | |a Schultheiß, Christoph |b 5 |
| 700 | 1 | _ | |a Widmer, Corinne |b 6 |
| 700 | 1 | _ | |a Heim, Dominik |b 7 |
| 700 | 1 | _ | |a Kasenda, Benjamin |b 8 |
| 700 | 1 | _ | |a Passweg, Jakob |b 9 |
| 700 | 1 | _ | |a Kobold, Sebastian |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Egli, Lukas |b 11 |
| 700 | 1 | _ | |a Coianiz, Nicolò |b 12 |
| 700 | 1 | _ | |a Chijioke, Obinna |b 13 |
| 700 | 1 | _ | |a Chiorazzi, Nicholas |b 14 |
| 700 | 1 | _ | |a Follo, Marie |b 15 |
| 700 | 1 | _ | |a Läubli, Heinz |b 16 |
| 700 | 1 | _ | |a Peipp, Matthias |b 17 |
| 700 | 1 | _ | |a Binder, Mascha |b 18 |
| 773 | _ | _ | |a DOI:10.3324/haematol.2025.287697 |0 PERI:(DE-600)2805244-4 |p nn |t Haematologica |v nn |y 2025 |x 0390-6078 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:304502 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-06-05T07:07:08Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-06-05T07:07:08Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Peer review |d 2023-06-05T07:07:08Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-20 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-20 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-20 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-20 |
| 920 | 1 | _ | |0 I:(DE-He78)MU01-20160331 |k MU01 |l DKTK Koordinierungsstelle München |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)MU01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|